Hypertension Patents (Class 514/15.7)
  • Patent number: 10368774
    Abstract: A health care system acquires data determines whether a patient is at risk of hypervolemia or hypovolemia. The method comprises (a) acquiring from a device memory a patient's absolute intrathoracic impedance data over a pre-specified time period, (b) determining a running average of the intrathoracic impedance data over the pre-specified time period, and (c) determining by the system whether the running average of the intrathoracic impedance data over the pre-specified time period exceeds one of a first and second range, the first range being a higher value boundary of intrathoracic electrical impedance and the second range being a lower value boundary of intrathoracic electrical impedance.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: August 6, 2019
    Assignee: Medtronic, Inc.
    Inventors: Vinod Sharma, Jodi L Redemske
  • Patent number: 10082506
    Abstract: The present disclosure provides for methods of diagnosing and treating bacterial infections. Human Intelectin 1 (hIntL-1) has been shown to bind selectively to glycan components on bacteria including Streptococcus pneumonia, Proteus mirabilis, Proteus vulgaris, Klebsiella pneumonia and Yersinia pestis. This interaction can be targeted to identify, purify and therapeutically target such organisms.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: September 25, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Laura L. Kiessling, Darryl A. Wesener, Kittikhun Wangkanont
  • Patent number: 9572856
    Abstract: A method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient.
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: February 21, 2017
    Assignee: The George Washington University a Congressionally Chartered Not-for-Profit Corporation
    Inventor: Lakhmir Chawla
  • Patent number: 9181281
    Abstract: A new class of neuramidase inhibitor prodrugs is provided characterized by a prodrug moiety of a carboxyl group modified to form a carbonyl ethoxy amino acid, a carbonyl ethoxy dipeptide or a carbonyl ethoxy tripeptide, a guanidine group modified to form a carbonyl ethoxy amino acid, a carbonyl ethoxy dipeptide, a carbonyl ethoxy tripeptide; a primary alcohol modified to form an esterified single amino acid, dipeptide or tripeptide of zanavimir of the unaltered therapeutic agent. Exemplary therapeutic agents so modified to form prodrugs include zanavimir, oseltamivir and peramivir. The prodrug has increased oral bioavailability relative to the unaltered neuraminidase inhibitor and is effective in the inhibition of viral infections involving neuraminidase in the viral reproductive cycle.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: November 10, 2015
    Assignee: SineVir Therapeutics LLC
    Inventors: John Hilfinger, Gordon Amidon
  • Patent number: 9045524
    Abstract: The present invention relates to compounds of Formula I, II, IVC, VIIIC, IXC, or XC and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, II, IVC, VIIIC, IXC, or XC are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases). Processes for synthesizing tripeptides are provided.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: June 2, 2015
    Assignee: NOVAGENESIS FOUNDATION
    Inventors: Jan-Eric Ahlfors, Khalid Mekouar
  • Patent number: 9034824
    Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: May 19, 2015
    Assignees: ONEDAY—BIOTECH AND PHARMA LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
  • Patent number: 9029327
    Abstract: Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence (Formula?I) (SEQ?ID?NO:?1) (X1)m(X2)n(X3)oX4X5HPX6, for treating and/or preventing a physical disorder associated with the renin-activated angiotensin system, wherein X1 is G or D, X2 is A, P, M, G, or R, X3 is G, A, H, or V, X4 is S, A, D, or Y, X5 is A, D, H, S, N, or I, X6 is A, L or F, wherein m, n and o are independently 0 or 1 under the premise that when o is 0 m and n are 0 and when n is 0 m is 0, and wherein the peptide is not DRVYIHPF (SEQ ID NO:4).
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: May 12, 2015
    Assignee: Affiris AG
    Inventors: Günther Staffler, Petra Lührs, Andreas Mairhofer, Frank Mattner, Walter Schmidt, Andrea Dolischka
  • Patent number: 9029505
    Abstract: The present invention provides modified Vasoactive Intestinal Peptides (VIPs), encoding polynucleotides and vectors, as well as pharmaceutical compositions comprising the same. The invention further provides methods of making and using the modified VIP agents. In accordance with the invention the VIP exhibits an extended circulatory half-life, receptor-binding or biological potency, and/or altered receptor binding profile with respect to unmodified VIP.
    Type: Grant
    Filed: August 16, 2010
    Date of Patent: May 12, 2015
    Assignee: Phasebio Pharmaceuticals, Inc.
    Inventors: Homayoun Sadeghi, Suzanne Dagher, Andrew Turner
  • Publication number: 20150126432
    Abstract: Compounds of formula (I), salts thereof, and compositions and uses thereof are described. The compounds are useful as V1a vasopressin agonists, for the treatment of e.g., complications of cirrhosis, including bacterial peritonitis, HRS2 and refractory ascites.
    Type: Application
    Filed: May 9, 2013
    Publication date: May 7, 2015
    Inventors: Kazimierz Wisniewski, Geoffrey S. Harris, Robert Felix Galyean
  • Publication number: 20150119332
    Abstract: The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform-selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments.
    Type: Application
    Filed: November 14, 2013
    Publication date: April 30, 2015
    Applicants: UNIVERSITY OF UTAH RESEARCH FOUNDATION, THE UNITED STATES GOVERNMENT, AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventor: Matthew A. Movsesian
  • Publication number: 20150111829
    Abstract: The present invention is based on the discovery that a VIP having a binding preference for VPAC2 can provide long-acting blood pressure control synergistically with concomitant anti-hypertensive therapies. Accordingly, methods and compositions useful for the treatment and/or amelioration of hypertension are provided.
    Type: Application
    Filed: June 6, 2012
    Publication date: April 23, 2015
    Applicant: PHASEBIO PHARMACEUTICALS, INC.
    Inventors: Lynne M. Georgopoulos, Susan Arnold
  • Publication number: 20150065424
    Abstract: The invention relates to composition comprising a pharmaceutically effective amount of one or more functional vasoactive intestinal peptide (VIP) fragments, and the use of those compositions in the treatment of fibrosis, hypertension and other disorder.
    Type: Application
    Filed: November 17, 2014
    Publication date: March 5, 2015
    Applicant: VECTUS BIOSYSTEMS LIMITED
    Inventor: Karen Annette Duggan
  • Publication number: 20150031604
    Abstract: The invention provides a cyclic polypeptide of Formula I (SEQ ID NO: 1): X1-R-X3-X4-L-S-X7-X8-X9-X10-X11-X12-X13??I or an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein X1, X3, X4, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor.
    Type: Application
    Filed: July 21, 2014
    Publication date: January 29, 2015
    Applicant: NOVARTIS AG
    Inventors: Frederic ZECRI, Philipp GROSCHE, Kayo YASOSHIMA, Hongjuan ZHAO, Jun Yuan, Aimee Richardson USERA, Changgang LOU, Aaron KANTER, Alexandra Marshall BRUCE, Carla Giumaraes
  • Publication number: 20150030594
    Abstract: The invention provides a bioconjugates comprising a synthetic polypeptide of Formula I? (SEQ ID NO: 1): or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein and a half-life extending moiety wherein the peptide and the half-life extending moiety are covalently linked or fuse, optionally via a linker. The polypeptides are agonist of the APJ receptor.
    Type: Application
    Filed: July 21, 2014
    Publication date: January 29, 2015
    Applicant: NOVARTIS AG
    Inventors: Jun YUAN, Frederic ZECRI, Philipp GROSCHE, Hongjuan ZHAO, Andrei GOLOSOV, Kayo YASOSHIMA, David Thomas PARKER, Eric PETERS, Aimee Richardson USERA, Shari Lynn CAPLAN, Aaron KANTER, Changgang LOU, Carla Guimaraes
  • Patent number: 8940685
    Abstract: The present invention discloses a method for producing antihypertensive active peptides with corn germ protein as the material. The method comprises an alkali-heat treatment and continuous enzymolysis of the corn germ protein. The components with molecular weight less than 1000 Da in the active peptides obtained according to the present method account for more than 92%, and alanine-tyrosine (Ala-Tyr, AY) as the characteristic peptide fragments in the antihypertensive peptides accounts for more than 0.6%, so that the active peptides have a good ACE inhibitory activity in vitro as well as stability against temperature, pH and major gastrointestinal digestive enzymes, and have a significant effect of lowering blood pressure on spontaneous hypertension rats in vivo. The active peptides can be applied as a new functional nutrient to development and production of food, health food and pharmaceutical.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: January 27, 2015
    Assignee: China National Research Institute of Food and Fermentation Industries
    Inventors: Muyi Cai, Ruizeng Gu, Weixue Yi, Jun Lu, Yong Ma, Zhe Dong, Yaguang Xu, Xingchang Pan, Yongqing Ma, Feng Lin, Zhentao Jin, Liang Chen, Lu Lu, Wenying Liu
  • Patent number: 8937039
    Abstract: The present invention provides peptide-based peroxidase inhibitors having the formula AA1-AA2-AA3, wherein AA1 is a positively charged, negatively charged or neutral amino acid, AA2 is a redox active amino acid, and AA3 is an amino acid possessing a reducing potential such that AA3 is capable of undergoing a redox reaction with a radical of amino acid AA2 or a retro or retro-inverso analog thereof. The result of such a combination is a highly effective inhibitor of peroxidase activity that has potent anti-inflammatory properties in widely diverse models of vascular disease and injury. Exemplary tripeptides effectively inhibit peroxidase mediated LDL oxidation, increase vasodilation in SCD mice, inhibit eosinophil infiltration and collagen deposition in asthma mice, inhibit acute lung injury, and decrease ischemic injury of the heart.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: January 20, 2015
    Assignee: The Medical College of Wisconsin, Inc.
    Inventors: Hao Zhang, Yang Shi, Hao Xu, Kirkwood A. Pritchard, Jr.
  • Publication number: 20150018278
    Abstract: The object of the invention is based on inhibiting specific phosphorylation on Thr248 and/or Thr250 residues of human transcription factor E2F4 to inhibit somatic endoreduplication processes in postmitotic cells which may be associated with various pathological conditions. The invention covers all currently known methods for the specific inhibition of protein phosphorylation (including the expression of mutant forms of E2F4 without Thr residues phosphorylated by p38MAPK) or methods developed in the future that may be applied to Thr-248 and/or Thr-250 residues of human transcription factor E2F4.
    Type: Application
    Filed: November 15, 2012
    Publication date: January 15, 2015
    Inventor: Jose Maria Frade Lopez
  • Publication number: 20150010531
    Abstract: The present invention relates to a method for the treatment of vascular dysfunction, reducing ischemic pain and/or treatment of a vascular disease comprising administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof to a patient in need of such treatment. The vascular dysfunction, ischemic pain and/or vascular disease may be associated with impaired endothelium mediated vasodilatation, a reduced eNOS activity, and/or a reduced NO bioavailability. The patient may be suffering from a disease selected from angina pectoris, ischemic heart disease, peripheral artery disease, systolic hypertension, migraine, type 2 diabetes and erectile dysfunction.
    Type: Application
    Filed: July 31, 2014
    Publication date: January 8, 2015
    Applicant: ANNEXIN PHARMACEUTICALS AB
    Inventors: Johan FROSTEGÅRD, Knut PETTERSSON
  • Patent number: 8921306
    Abstract: The present invention relates to nociceptin peptide mimetics that have ?-helical structures and bind to and modulate the opioid receptor-like-1 (ORL-1) receptor. The peptide mimetics are constrained cyclic nociceptin analogs which have either agonist or antagonist activity. Pharmaceutical compositions comprising the nociceptin peptide mimetics and methods of treating or preventing a disease or condition ameliorated by modulating the ORL-1 receptor are also described.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: December 30, 2014
    Assignee: The University of Queensland
    Inventors: David Fairlie, Rosemary Sharon Harrison, Nicholas Evan Shepherd
  • Patent number: 8916517
    Abstract: This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: December 23, 2014
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: David H. Coy, Jerome L. Maderdrut, Min Li
  • Patent number: 8916523
    Abstract: The invention relates to composition comprising a pharmaceutically effective amount of one or more functional vasoactive intestinal peptide (VIP) fragments, and the use of those compositions in the treatment of fibrosis, hypertension and other disorder.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: December 23, 2014
    Assignee: Vectus Biosystems Limited
    Inventor: Karen Annette Duggan
  • Publication number: 20140370034
    Abstract: The present invention is related to a nucleic acid molecule binding to SDF-1, whereby the nucleic acid molecule influences migration of cells.
    Type: Application
    Filed: July 6, 2014
    Publication date: December 18, 2014
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse
  • Publication number: 20140357549
    Abstract: The present invention relates to inhibitors of Nox1-dependent reactive oxygen species production and their use in the treatment of disorders associated with reactive oxygen species, such as hypertension and cancer.
    Type: Application
    Filed: May 13, 2014
    Publication date: December 4, 2014
    Applicant: University of Pittsburgh - Of The Commonwealth System of Higher Education
    Inventors: Daniel J. Ranayhossaini, Patrick Joseph Pagano
  • Publication number: 20140348850
    Abstract: The present invention relates to methods of reducing blood pressure in a subject by administering a plasma kallikrein inhibitor.
    Type: Application
    Filed: August 15, 2014
    Publication date: November 27, 2014
    Inventors: Edward P. Feener, Allen Clermont
  • Patent number: 8883145
    Abstract: Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: November 11, 2014
    Assignee: Oncomed Pharmaceuticals, Inc.
    Inventors: Robert Joseph Stagg, Steven Eugene Benner
  • Publication number: 20140329738
    Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.
    Type: Application
    Filed: March 28, 2014
    Publication date: November 6, 2014
    Inventors: Kunwar Shailubhai, Gary S. Jacob
  • Patent number: 8865155
    Abstract: New Lactococcus lactis strains, NRRL B-50571 and NRRL B-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower LDL-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: October 21, 2014
    Assignees: Centro de Investigacion en Alimentacion y Desarrollo, A.C. (CIAD)
    Inventors: Belinda Vallejo Galland, Aarón Fernando González Córdova, José Carlos Rodríguez Figueroa
  • Publication number: 20140303068
    Abstract: The present invention relates generally to a method of reducing unwanted airway tissue mucus secretion in a mammal and to agents useful for same. More particularly, the present invention relates to a method of reducing airway tissue mucus hypersecretion in a mammal by downregulating the functional level of activin or upregulating the functional level of follistatin. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by airway tissue mucus dysfunction, such as overproduction of mucus or decreased mucus clearance, and where a reduction in mucus secretion levels would thereby alleviate the condition.
    Type: Application
    Filed: October 26, 2012
    Publication date: October 9, 2014
    Inventors: Robyn O'Hehir, Charles Hardy, David De Kretser
  • Publication number: 20140296150
    Abstract: The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: August 10, 2012
    Publication date: October 2, 2014
    Applicant: Ascendis Pharma A/S
    Inventors: Ulrich Hersel, Harald Rau, Torben Lessmann, Nicola Bisek, Guillaume Maitro, Kennett Sprogøe, Thomas Wegge, Oliver Keil, Joachim Zettler
  • Patent number: 8822413
    Abstract: A bifunctional hormone exhibiting an alpha-MSH activity and a natriuretic peptide activity is described. The bifunctional hormone comprises for example a first domain having alpha-MSH related hormonal activity covalently linked to a second domain having natriuretic peptide related hormonal activity. The bifunctional hormone of the present invention is useful for example for the prevention and/or treatment of renal related diseases or conditions, such as acute renal failure (ARF) or acute kidney injury (AKI).
    Type: Grant
    Filed: July 7, 2008
    Date of Patent: September 2, 2014
    Assignee: Theratechnologies Inc.
    Inventors: Krishna G. Peri, Abdelkrim Habi
  • Patent number: 8802635
    Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: August 12, 2014
    Assignees: Oneday—Biotech And Pharma Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
  • Publication number: 20140221271
    Abstract: Disclosed herein are pharmaceutical compositions having the sequence Arg-Ser-Cys-Ile-Asp-Thr-Ile-Pro-Lys-Ser-Arg-Cys-Thr-Ala-Phe-Gln-Cys-Lys-His-Ser-Xaa-Lys-Tyr-Arg-Leu-Ser-Phe-Cys-Arg-Lys-Thr-Cys-Gly-Thr-Cys (SEQ ID NO: 1). The disclosed compositions can include an acid or amide at the C-terminus of SEQ ID NO: 1 and the polypeptide can be attached to an organic or inorganic chemical entity that has an anionic charge. The polypeptide can be detectably labeled for diagnostic purposes. Methods of manufacturing and using the pharmaceutical compounds are also disclosed.
    Type: Application
    Filed: June 5, 2012
    Publication date: August 7, 2014
    Inventors: Shawn P Iadonato, Eric J Tarcha
  • Patent number: 8785386
    Abstract: The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is represented by general formula (1) wherein R1 represents a —CO—(CH2)n—COR2 group (wherein n is an integer of 1 to 4, and R2 is (2-1) a hydroxy group; (2-2) a lower alkoxy group optionally substituted with a hydroxy group, a lower alkanoyl group, a lower alkanoyloxy group, a lower alkoxycarbonyloxy group, a cycloalkyloxycarbonyloxy group, or 5-methyl-2-oxo-1,3-dioxol-4-yl; or (2-3) an amino group optionally substituted with a hydroxy-lower alkyl group), or the like.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: July 22, 2014
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Kazumi Kondo, Yasuhiro Menjo, Takahiro Tomoyasu, Shin Miyamura, Yuso Tomohira, Takakuni Matsuda, Keigo Yamada, Yusuke Kato
  • Patent number: 8765677
    Abstract: This invention relates to an isolated, synthetic or recombinant peptide, wherein the peptide comprises the sequence: C K G K G A Xaa1 C R Xaa2 Xaa3 Xaa4 Y Xaa5 C C Xaa6 G Xaa7 C R Xaa8 Xaa9 R C SEQ ID NO: 1 wherein Xaa1, Xaa3, Xaa4, Xaa6, Xaa7 and Xaa8 are independently selected from serine and threonine; Xaa2 is selected from arginine and lysine; Xaa5 is selected from aspartic acid and glutamic acid; and Xaa9 is selected from glycine, alanine, valine, leucine and isoleucine.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: July 1, 2014
    Assignees: The University of Queensland, The University of Sydney
    Inventors: Richard Lewis, David John Adams, Geza Berecki, Roger Drinkwater, Paul Francis Alewood, MacDonald James Christie
  • Patent number: 8759291
    Abstract: Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: June 24, 2014
    Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP
    Inventors: Andrew A. Young, Will Vine, Kathryn Prickett, Nigel R.A. Beeley
  • Publication number: 20140155315
    Abstract: The invention provides a synthetic polypeptide of Formula I? (SEQ ID NO: 1): X1-X2-X3-R—X5-X6-X7-X8-X9-X10-X11-X12-X13??I or an amide, an ester or a salt thereof, wherein X1, X2, X3, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia.
    Type: Application
    Filed: November 18, 2013
    Publication date: June 5, 2014
    Applicant: NOVARTIS AG
    Inventors: Frédéric Zecri, Kayo Yasoshima, Philipp Grosche, Jun Yuan, Hongjuan Zhao
  • Patent number: 8741861
    Abstract: The present invention discloses multiple treatment regimens for vascular-related diseases and disorders. The present invention provides for methods of treating vascular-related disorders based on gene expression studies from samples collected from individuals having symptoms of vascular-related disorders. Additionally, methods are disclosed involving diagnostic techniques to focus treatment regimens. Finally, methods of treating vascular-related disorder involving targeting microRNAs are also disclosed.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: June 3, 2014
    Assignee: Vascular Biosciences
    Inventor: David M. Mann
  • Publication number: 20140142022
    Abstract: The invention provides a synthetic polypeptide of Formula I?: or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia.
    Type: Application
    Filed: January 28, 2014
    Publication date: May 22, 2014
    Inventors: Frederic ZECRI, Andrei GOLOSOV, Philipp GROSCHE, Kayo YASOSHIMA, Hongjuan ZHAO, Qi-Ying HU, Hidetomo IMASE, David Thomas PARKER
  • Publication number: 20140127235
    Abstract: Disclosed herein are novel methods for controlling blood pressure that involve targeting HK alpha. Also, disclosed are novel compositions for treating elevated blood pressure that include administering an agent that disrupts HK alpha expression or activity. Methods of screening novel antihypertensives are disclosed as well.
    Type: Application
    Filed: April 6, 2012
    Publication date: May 8, 2014
    Inventor: Charles Wingo
  • Publication number: 20140100166
    Abstract: The disclosure provides methods of preventing or treating heart failure in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.
    Type: Application
    Filed: September 24, 2013
    Publication date: April 10, 2014
    Applicants: University of Washington, Cornell University
    Inventors: Hazel H. Szeto, Peter S. Rabinovitch, Dao-Fu Dai
  • Publication number: 20140094409
    Abstract: Brain prorenin and the (pro)renin receptor (PRR) have a functional role in the development of hypertension. The present disclosure presents functional PRR antagonistic peptides (e.g., PR10, PR20, PR30, and PR40). In addition, modified peptides comprising one or more thioether-bridges that are stable and strong PRR antagonists are also provided. Methods for treating and preventing hypertension, including neurogenic hypertension, and diabetes with a PRR antagonist are also provided.
    Type: Application
    Filed: September 19, 2013
    Publication date: April 3, 2014
    Inventor: Yumei FENG
  • Patent number: 8673847
    Abstract: The present invention provides peptide-based peroxidase inhibitors having the formula AA1-AA2-AA3, wherein AA1 is a positively charged, negatively charged or neutral amino acid, AA2 is a redox active amino acid, and AA3 is an amino acid possessing a reducing potential such that AA3 is capable of undergoing a redox reaction with a radical of amino acid AA2 or a retro or retro-inverso analog thereof. The result of such a combination is a highly effective inhibitor of peroxidase activity that has potent anti-inflammatory properties in widely diverse models of vascular disease and injury. Exemplary tripeptides effectively inhibit peroxidase mediated LDL oxidation, increase vasodilation in SCD mice, inhibit eosinophil infiltration and collagen deposition in asthma mice, inhibit acute lung injury, and decrease ischemic injury of the heart.
    Type: Grant
    Filed: October 5, 2010
    Date of Patent: March 18, 2014
    Assignee: The Medical College of Wisconsin, Inc.
    Inventors: Hao Zhang, Yang Shi, Hao Xu, Kirkwood A. Pritchard, Jr.
  • Publication number: 20140072650
    Abstract: Disclosed is an antihypertensive composition containing as an active ingredient a gelatin extract made from the skins of a skate ray and a peptide isolated from the extract. The present invention is directed to a pharmaceutical composition for a hypertension prevention and therapy containing as an active ingredient a hydrolysate of a gelatin extract isolated from the skins of a skate ray, a method for preparing a hydrolysate of a gelatin extract made from the skins of a skate ray, and the use of a new peptide having an antihypertensive activity isolated and purified from the hydrolysate.
    Type: Application
    Filed: October 31, 2012
    Publication date: March 13, 2014
    Applicant: Pukyong National University Industry-University Cooperation Foundation
    Inventors: Se-Kwon KIM, Bo-Mi RYU
  • Patent number: 8669229
    Abstract: The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is represented by general formula (1) wherein R1 represents a —CO—(CH2)n—COR2 group (wherein n is an integer of 1 to 4, and R2 is (2-1) a hydroxy group; (2-2) a lower alkoxy group optionally substituted with a hydroxy group, a lower alkanoyl group, a lower alkanoyloxy group, a lower alkoxycarbonyloxy group, a cycloalkyloxycarbonyloxy group, or 5-methyl-2-oxo-1,3-dioxo-4-yl; or (2-3) an amino group optionally substituted with a hydroxy-lower alkyl group), or the like.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: March 11, 2014
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Kazumi Kondo, Yasuhiro Menjo, Takahiro Tomoyasu, Shin Miyamura, Yuso Tomohira, Takakuni Matsuda, Keigo Yamada, Yusuke Kato
  • Publication number: 20140018296
    Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided.
    Type: Application
    Filed: September 23, 2013
    Publication date: January 16, 2014
    Applicant: Alcon Research, Ltd.
    Inventor: Jon E. Chatterton
  • Publication number: 20140018286
    Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.
    Type: Application
    Filed: September 26, 2013
    Publication date: January 16, 2014
    Applicant: NOVO NORDISK A/S
    Inventors: Lauge Schaeffer, Thomas Kruse, Henning Thoegersen
  • Publication number: 20140011732
    Abstract: The invention relates to protracted peptide derivatives such as Glucagon-Like Peptide-1 (GLP-1), exendin-4, and analogues thereof, as well as therapeutic uses thereof. The peptide derivative of the invention comprises a peptide wherein at least one amino acid residue is derivatized with A-B—C—, or A-B—C-D-. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, have a low ratio of binding affinity to the GLP-1 receptor in the presence of high/low albumin concentrations, have long half-lives, and have a high affinity of binding to albumin, all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.
    Type: Application
    Filed: June 28, 2013
    Publication date: January 9, 2014
    Applicant: NOVO NORDISK A/S
    Inventors: Jane Spetzler, Lauge Schaeffer, Jesper Lau, Thomas Kruse, Patrick William Garibay, Soeren Oestergaard, Steffen Reedtz-Runge, Henning Thoegersen
  • Publication number: 20140011737
    Abstract: The present invention features compositions and methods for treating and preventing a metabolic syndrome featuring the collagen triple helix repeat containing-1 (Cthrc1) protein.
    Type: Application
    Filed: July 3, 2013
    Publication date: January 9, 2014
    Applicant: MAINE MEDICAL CENTER
    Inventor: Volkhard Lindner
  • Publication number: 20140011742
    Abstract: A process for treating a protein before hydrolytic digestion, the process comprising exposing the protein to at least one cycle of microwave irradiation to produce a microwave treated protein containing one or more bioactive peptides. Further hydrolyzing the microwave treated protein to release at least one of the one or more bioactive peptides. A pharmaceutical composition, supplement and food product including the microwave treated protein or the one or more released bioactive peptides.
    Type: Application
    Filed: December 8, 2011
    Publication date: January 9, 2014
    Applicant: MCGILL UNIVERSITY
    Inventors: Jacqueline Sedman, Ashraf A. Ismail, Ahmed I. Gomaa
  • Patent number: 8613920
    Abstract: The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to A?. The invention also provides monitoring regimes that can assess changes in symptoms or signs of the patient following treatment.
    Type: Grant
    Filed: July 27, 2007
    Date of Patent: December 24, 2013
    Assignees: Janssen Alzheimer Immunotherapy, Wyeth LLC
    Inventors: Ivan Lieberburg, James Callaway, Michael Grundman